Personalized therapy guided by single‐cell transcriptomic analysis in relapsed and refractory <i>KMT2A::MLLT10</i><scp>AML</scp> with extensive extramedullary infiltration: A case report-Reference-Cited by-同舟云学术

Personalized therapy guided by single‐cell transcriptomic analysis in relapsed and refractory KMT2A::MLLT10AML with extensive extramedullary infiltration: A case report

Published:2024-05-13 Issue: Volume: Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Wang Rong¹,Wu Yue²,Xue Ruicong¹,Shi Ting³,Gu Haifeng²,Yang Yichen²,Wu Weizhen²,Yang Yunmei²,Sun Shu³,Zhu Hong‐Hu³⁴^ORCID

Affiliation:

1. Department of Hematology First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang China

2. Department of Geriatrics First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang China

3. Department of Hematology, Beijing Chao‐Yang Hospital Capital Medical University Beijing China

4. Chinese Institutes for Medical Research Beijing China

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.19522

Reference15 articles.

1. C1Q labels a highly aggressive macrophage-like leukemia population indicating extramedullary infiltration and relapse

2. Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/ myelodysplastic syndromes after a first transplantation.

3. Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change

4. Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse

5. Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1